IMMUNOVANT INC. - COMMON STOCK

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

30 ديسمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

12 نوفمبر 2021 12:18:05 بحسب Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

05 نوفمبر 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Immunovant to Participate in Roivant R&D Day 2021

27 سبتمبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Immunovant Appoints Renee Barnett as Chief Financial Officer

15 سبتمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended June 30, 2021

09 أغسطس 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Immunovant to Report Financial Results for Quarter Ended June 30, 2021

06 أغسطس 2021 16:22:27 بحسب Nasdaq GlobeNewswire

Immunovant Receives $200 Million Strategic Investment from Roivant Sciences

02 أغسطس 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021

01 يونيو 2021 07:31:18 بحسب Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020

16 فبراير 2021 08:00:04 بحسب Nasdaq GlobeNewswire

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

02 فبراير 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

12 يناير 2021 17:00:00 بحسب Nasdaq GlobeNewswire